Drug treatment of hyperuricemia to prevent cardiovascular outcomes: Are we there yet?

American Journal of Cardiovascular Drugs

Volumn 12, Issue 1, 2012, Pages 1-6

  Gaffo, Angelo L ^a,b   Saag, Kenneth G ^b  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Allopurinol; Coronary artery disease; Heart failure; Hypertension; Hyperuricaemia; Metabolic syndrome; Stroke; Xanthine oxidase inhibitors.

Indexed keywords

ALLOPURINOL; CAPTOPRIL; DIURETIC AGENT; FEBUXOSTAT; LOSARTAN; OTERACIL; PEGLOTICASE; PLACEBO; RASBURICASE; SUPEROXIDE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIURETIC THERAPY; DRESS SYNDROME; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL INTOLERANCE; GOUT; HEART DEATH; HEART FAILURE; HUMAN; HYPERTENSION; HYPERURICEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIVER TOXICITY; META ANALYSIS; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VASOCONSTRICTION; WEIGHT REDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERURICEMIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84856271074     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11594580-000000000-00000     Document Type: Review

References (60)

1. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15 (2): 189-92
2. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82 (3): 421-6
3. Puig JG, de Miguel E, Castillo MC, et al. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008; 27 (6): 592-5 (Pubitemid 351948570)
4. Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther 2009; 11 (4): 240. Epub 2009 Aug 19
5. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumaticconditions inthe United States: Part II. Arthritis Rheum 2007; 58 (1): 26-35
6. Klemp P, Stansfield SA, Castle B, et al. Goutison the increase in New Zealand. Ann Rheum Dis 1997; 56 (1): 22-6
7. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002; 283 (5): F1105-10 (Pubitemid 35192478)
8. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67 (1): 237-47 (Pubitemid 40019245)
9. Sanchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008; 23 (4): 1179-85 (Pubitemid 351767502)
10. Sanchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyper-uricemia. Nephron Physiol 2008; 108 (4): 69-78
11. Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26 (2): 269-75
12. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295 (4): F1134-41
13. Yu MA, Sanchez-Lozada LG, Johnson RJ, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hyper-tens 2010; 28 (6): 1234-42
14. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417 (6887): 447-52 (Pubitemid 34563537)
15. Hunt SC, Stephenson SH, Hopkins PN, et al. Predictors of an increased risk of future hypertension in Utah: a screening analysis. Hypertension 1991; 17 (6 Pt 2): 969-76
16. Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24 (5): 531-6 (Pubitemid 33048919)
17. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49 (2): 298-303 (Pubitemid 46143005)
18. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42 (4): 474-80 (Pubitemid 37237341)
19. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48 (6): 1037-42 (Pubitemid 44772705)
20. Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27 (11): 835-41 (Pubitemid 40309449)
21. Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18 (6): 523-30 (Pubitemid 36899556)
22. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006; 48 (6): 1031-6 (Pubitemid 44772704)
23. Selby JV, Friedman GD, Quesenberry Jr CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131 (6): 1017-27 (Pubitemid 20178623)
24. Shankar A, Klein R, Klein BE, et al. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 2006; 20 (12): 937-45 (Pubitemid 44782827)
25. Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45 (1): 28-33 (Pubitemid 40066409)
26. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19 (7): 1209-15 (Pubitemid 32595276)
27. Gaffo AL, Jacobs Jr DR, Sijtsma F, et al. Serum urate levelsin young adults are associated with the risk of incident hypertension: findings from the Coronary Artery Risk Developmentin Young Adults (CARDIA) cohort. In: Meeting of the American College of Rheumatology. Atlanta (GA): 2010
28. Grayson PC, Kim SY, Lavalley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63 (1): 102-10
29. Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 2009; 55 (11): 2026-34
30. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300 (8): 924-32
31. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39 (4): 1227-33 (Pubitemid 350193621)
32. US National Institute of Health online. Available from URL: http://clinicaltrials. gov/ct2/show/NCT00241839?term= allopurinol+AND+hypertension&rank=3 Accessed 2011 Jul 11
33. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62 (2): 170-80
34. Chen JH, Chuang SY, Chen HJ, et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61 (2): 225-32
35. Tatli E, Aktoz M, Buyuklu M, et al. The relationship between coronary artery disease and uric acid levelsinyoung patients with acute myocardial infarction. Cardiol J 2008; 15 (1): 21-5 (Pubitemid 351425097)
36. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61 (7): 885-92
37. Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69 (14): 1418-23 (Pubitemid 47511463)
38. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556-62
39. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83, 683 Austrian men. Clin Chem 2008; 54 (2): 273-84 (Pubitemid 351302628)
40. Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28, 613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125 (2): 232-9
41. Wu AH, Ghali JK, Neuberg GW, et al. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010; 160 (5): 928-33
42. Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006; 12 (7): 491-8 (Pubitemid 44307706)
43. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol 2008; 51 (24): 2301-9 (Pubitemid 351783365)
44. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131 (1): 7-13 (Pubitemid 29310011)
45. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283 (18): 2404-10 (Pubitemid 30257539)
46. Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266 (21): 3008-11
47. Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998 Aug; 47 (8): 929-33 (Pubitemid 28364609)
48. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructoseinduced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290 (3): F625-31 (Pubitemid 43724964)
49. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33 (Pubitemid 34761611)
50. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76 (1): 47-56 (Pubitemid 14216359)
51. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65 (10): 1312-24 (Pubitemid 44620440)
52. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (8): 741-52 (Pubitemid 47295641)
53. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004; 51 (6): 1023-9 (Pubitemid 39648198)
54. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52 (1): 283-9 (Pubitemid 40129260)
55. Gaffo AL, Roseman JM, Jacobs Jr DR, et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the coronary artery risk development in young adults (CARDIA) cohort. Ann Rheum Dis 2010; 69 (11): 1965-70
56. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375 (9732): 2161-7
57. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2010; 377 (9760): 165-77
58. European Medicines Agency online. Available from URL: http://www.emea. europa.eu/humandocs/Humans/EPAR/adenuric/adenuric.htm. Accessed 2011 July 11
59. Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59 (11): 1580-8
60. Kim SY, Martin N, Hsia EC, et al. Management of aortic disease in Marfan Syndrome: a decision analysis. Arch Intern Med 2005; 165 (7): 749-55 (Pubitemid 40569427)